ABSTRACT D-Glucosamine is toxic to several malignant cell lines and in vivo tumors at concentrations that have little effect upon normal host tissues. Evidence is presented to support the hypothesis that cellular membranes may be the primary targets of glucosamine's tumoricidal activity. Treatment of rat C6 glioma cells with a cytotoxic concentration of glucosamine (20 mM) caused fragmentation of rough endoplasmic reticulum, proliferation of Golgi complexes, evagination of outer nuclear and mitochondrial membranes, and the accumulation of membranous vacuoles and lipid droplets in the cytoplasm. These changes were detected within the first 3 hr after treatment of cultures with glucosamine and became increasingly severe until cell lysis occurred between 24 and 48 hr of treatment. The cytotoxicity of glucosamine was potentiated by the local anesthetic lidocaine, and by other membrane-active drugs, at concentrations that were growth inhibitory but nonlytic. Most of these drugs possessed local anesthetic activity and inhibited glioma sterol synthesis. Within the same period of time required or ultrastructural changes in cellular membranes, glucosamine inhibited the incorporation of [2-14Clacetate into sterols and into an unidentified 400-dalton lipid that migrated close to sterols on thin-layer chromatograms. This inhibition was potentiated by lidocaine and increased over the same range of D-glucosamine concentrations that led to increased cell toxicity after a 48-hr treatment. These findings suggest that the effects of glucosamine upon cellular membranes may be central to its tumoricidal activity and that glucosamine, in combination with membrane-active drugs, may be useful in the treatment of certain types of tumors, particularly those of the central nervous system.
tumoricidal activity and that glucosamine, in combination with membrane-active drugs, may be useful in the treatment of certain types of tumors, particularly those of the central nervous system.
The drugs available for clinical treatment of cancer are believed to act as antiproliferative agents. They have little selectivity (1) and attack rapidly growing tissues by interfering with cell division, inducing unbalanced growth, disrupting nucleotide metabolism, intercalating with or modifying DNA, or altering chromosome structure (2) . Because of the diversity of proliferating host tissues (3), such agents are limited in clinical utility by their toxic side effects on normal host tissues. Although the antiproliferative drugs have a major role in the clinical treatment of cancer, an alternative basis for tumor chemotherapy would be valuable.
D-Glucosamine, a naturally occurring amino sugar, is an important carbohydrate component of many cellular glycoproteins, glycolipids, and glycosaminoglycans (4) (5) (6) (7) . It exhibits little toxicity toward normal host tissues, but is an effective lytic agent for several types of transplantable animal tumors and human tumor xenografts grown in athymic mice (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) .
The mechanisms of glucosamine cytotoxicity are complex
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and appear to involve the concatenation of several different effects (19) . The most prominent and rapidly occurring changes are produced in cellular membranes. Within the first 3 hr after its addition to cell cultures, D-glucosamine alters the ultrastructure of the plasma and intracellular membranes (17) (18) (19) , inhibits membrane transport of nucleosides (20) , increases nucleoside leakage to the extracellular space (20) , shifts the distribution of tritiated glucosamine incorporation from glycoproteins to glycolipids (19) , inhibits the flow of ['4C]acetate into sterols and lipids (19, 21) , potentiates the inhibition of cholesterol synthesis by local anesthetics (21) , and inhibits cell aggregation, homotypic cell sorting, and lectin agglutination (22) (23) (24) . These observations led us to postulate that the selective toxicity of D-glucosamine towards tumor cells might arise primarily from its effects upon cellular membranes (19 (28) .
Cells in plastic tissue-culture dishes were prepared for electron microscopy by washing in Puck's saline G, fixing with cacodylate-buffered 3% glutaraldehyde for 1 hr, postfixing with 1% osmium for 1 hr, staining with uranyl acetate for 1 hr, then dehydrating in ethanol and embedding in Epon-Araldite. Samples were silver-sectioned on a Porter-Blum ultramicrotome, poststained with uranyl acetate and lead citrate, and examined with a Zeiss EM 9S-2 electron microscope. 
RESULTS
Glucosamine/Lidocaine Cytotoxicity. Rat C6 glioma cells plated at moderate density (6 X 105 cells per 35-mm dish) grew rapidly and reached confluency within 48 hr ( Fig. 1 A and B) . Over 48 hr of incubation, D-glucosamine concentrations as low as 1 mM detectably inhibited growth; complete growth arrest occurred at about 10 mM ( Fig. 1 C and D) . With higher concentrations, cells were irreversibly injured and eventually lysed (Fig. 1E) . Addition of uridine, hypoxanthine, or adenosine (0.01-1 mM) did not prevent or enhance glucosamine toxicity. Adenosine (1 mM) inhibited culture growth by 50% at 48 hr of treatment. The effects of lidocaine were similar to those of glucosamine. Within 48 hr of incubation, some growth inhibition was evident with 1.25 mM lidocaine (Fig. 1F) ; growth arrest occurred at about 2.5 mM (Fig. 1G) and cell lysis at about 3.75 mM (Fig. 1H) .
When cultures were simultaneously incubated with both drugs, considerable potentiation of growth inhibition and irreversible cell injury occurred. A combination of 1.25 mM lidocaine and 1 mM glucosamine, for example, inhibited growth almost completely (Fig. 1I) . Elevating either drug even slightly induced some degree of irreversible cell injury, shown by the formation of highly refractile cells, ghosts, and cell debris ( Fig. 1 J and K) . Higher concentrations of the two drugs produced total lysis between 24 and 48 hr of treatment (Fig. 1L) . To determine whether the potentiation of glucosamine growth inhibition and cell lysis by lidocaine was additive or synergistic, we performed an isobologram analysis (29) ; the interaction between the two drugs was synergistic (Fig. 2) .
Membrane Effects of D-Glucosamine. As a preliminary step in identifying the mechanisms responsible for its cytotoxicity, we examined the ultrastructural effects of glucosamine upon rat C6 glioma cells. Cultures were incubated with a cytotoxic concentration of glucosamine (20 mM), but were collected for fixation at early times prior to the onset of actual lysis. By comparison with controls, cells treated with glucosamine displayed fragmentation of their rough endoplasmic reticulum, proliferation of the Golgi apparatus, budding of the outer membranes of mitochondria and nuclei, formation of membrane-bounded vacuoles (Fig. 3) (Fig. 4) . This effect reached a maximum of about 90% inhibition at 20 mM glucosamine. Preliminary mass spectroscopic studies suggest that the unidentified lipid is an oxygenated hydrocarbon with a mass of 400 daltons (S. J. '4C]acetate into this lipid, but did inhibit incorporation into the sterol fraction (Fig. 4) , which in glioma cells consists of cholesterol and desmosterol (21, 30 (Table 1) .
Glucosamine in Combination with Other MembraneActive Drugs. The pronounced effects of glucosamine upon a variety of cellular membrane systems, together with its ability to synergize with the membrane-active drug lidocaine in producing cytotoxicity, suggested to us that the primary mechanism of glucosamine cytotoxicity might involve effects upon cellular membranes rather than upon cell proliferation. If this hypothesis were correct, then various membrane-active drugs might be expected to potentiate the lytic effects of glucosamine.
Glioma cultures were incubated with papaverine, chlorprothixene, thioridazine, adiphenine, lidocaine, haloperidol, or ketamine either singly or in combination with glucosamine (Table 2) . Individually, each of these membrane-active drugs produced some degree of growth inhibition at pharmacological concentrations, but did not produce visible cell lysis. However, in combination with growth-inhibitory concentrations of glucosamine (3 or 10 mM), irreversible cell damage resulted. With each combination shown in Table 2 , the reduction in culture protein content was greater than would be expected for summation of mutually exclusive inhibitors (31 (16, (34) (35) (36) ; the second postulates that it disrupts the structure and function of cellular membrane systems (19) .
The nucleotide-depletion hypothesis arises from the ability of glucosamine to deplete cellular pools of nucleotides and their precursors in at least four different ways: (i) by trapping uridylate as a UDP-hexosamine complex and by ATP consumption during glucosamine phosphorylation (34-39); (ii) by inhibition of nucleotide salvage pathways (20, 40) ; (iii) by inhibiting the uptake of exogenous thymidine (20) ; and (iv) by promoting the cellular leakage of nucleotides and their metabolites (20, 34) .
However, no firm correlation has yet been established between any of these effects and the development of cytotoxicity. The induction of severe ATP and UTP depletion by glucosamine does not appear to be a sufficient condition for causing tumor cell lethality (34) . Glucosamine-induced uridylate trapping does not correlate 'with cytotoxicity (36, (41) (42) (43) . Glucosamine cytotoxicity is not prevented by exogenous uridine or by the purines hypoxanthine and adenosin6 (ref. 16 and this report). These observations suggest that glucosamine's cytotoxicity mechanism may differ from that proposed for the hepatotoxic amino sugar, galactosamine (36) .
The membrane theory of glucosamine cytotoxicity arises from the fact that the amino sugar induces a broad spectrum of changes in membrane ultrastructure and function and in the metabolic pathways by which membrane constituents are synthesized. Ultrastructurally, glucosamine causes the fragmentation or vesiculation of the plasma membrane and various intracellular membrane systems of rat C6 glioma cells in culture (Fig. 3) . These effects upon cellular membranes are early events in the development of glucosamine cytotoxicity. In vivo, glucosamine causes nuclear shrinkage, cytoplasmic retraction and vacuolization, dilation and fragmentation of the endoplasmic reticulum, and loss of mitochondrial cristae by tumor cells (13) . Glucosamine inhibits the membrane transport of thymidine (20) , promotes the transmembrane leakage of several nucleotide metabolites (20, 34) , and modifies the binding pattern of '25I-labeled fetal calf serum components to the cell surface (19) .
It inhibits the incorporation of acetate into sterols and an unidentified lipid (Fig. 4) , but promotes the flow-of tritiated glucosamine. into ceramide-Glc-Gal(AcNeu-AcNeu)-GalNAc-Gal (GDJ), ceramide-Glc-Gal(AcNeu)-GaINAc-Gal (GM1), ceramide-Glc-Gal(AcNeu)-GalNAc (GM2), and lactosyl ceramide (19) .
To further explore the possible involvement of membrane events in glucosamine cytotoxicity, we investigated the effects of glucosamine in combination with various membrane-active drugs. Lidocaine synergistically potentiated rat glial tumor cell lysis by glucosamine in culture (Figs. 1 and 2) . IndividWtlly, glucosamine inhibited [14C]acetate incorporation into sterols and an unidentified lipid, whereas lidocaine inhibited only the incorporation into sterols (Fig. 4 and Table 1 ). When cell cultures were simultaneously incubated with both drugs, there was an enhanced inhibition of acetate incorporation into both bands. This effect was rapid and was detectable within 1-3 hr after addition of the drugs. It preceded the onset of cell lysis by about 24 hr. We therefore suggest that the cytotoxicity of glucosamine and of the combination of glucosamine and lidocaine results from membrane alterations caused by inhibition of the synthesis of sterols and an unidentified lipid. The possibility that altered nucleotide pools might contribute to the production of these membrane lesions has not been investigated in the rat C6 glioma system. Early changes in plasma membranes of galactosamine-treated liver are prevented or reversed by treatments that prevent hepatotoxicity (e.g., provision of uridine) (44) .
Other membrane-active drugs also potentiated the cytotoxicity of glucosamine ( Table 2 ). These drugs differed considerably in their chemical structures and primary pharmacological activities. Among them were an aromatic amine (adiphenine), a benzylisoquinoline (papaverine), a butyrophenone (haloperidol), a cyclohexanone (ketamine), a phenothiazine (thioridazine), and a thioxanthine (chlorprothixene). Most of these drugs possess local anesthetic activity and inhibit acetate incorporation into sterols at concentrations similar to those used in the cytotoxicity experiments (21) . This latter observation lends further support to our suggestion that the inhibition of sterol synthesis may be central to the development of cytotoxicity by glucosamine and glucosamine in combination with other membrane-active drugs.
These findings raise the possibility that chemotherapy using glucosamine in combination with local anesthetics and related membrane-active drugs may provide a clinically valuable supplement to the use of antiproliferative agents in the management of certain neoplasms. Preliminary experiments suggest that certain of these combinations may be selectively toxic to several animal tumors in vivo and to human neural and glial tumor xenografts in athymic mice (33 
